 |
8 Diseases |  |
0 Trials |
|
0 Trials |  |
17 News |  |
- MK-8435 / Merck (MSD)
Determination of glycine transporter 1 levels with [3H]-NFPS binding in hemi-parkinsonian rats with L-DOPA induced dyskinesia (Poster Station: 24) - Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_1513;
On the other hand, administration of L-DOPA appears to be associated with increased GlyT1 levels in the subthalamic nucleus. Further studies are warranted to shed light on the mechanisms and circuitry underlying GlyT1 involvement in PD and dyskinesia.
- || MK-8435 / Merck (MSD)
Trial completion: Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects (clinicaltrials.gov) - Mar 3, 2022
P1, N=15, Completed, Sponsor: Yale University
Further studies are warranted to shed light on the mechanisms and circuitry underlying GlyT1 involvement in PD and dyskinesia. Active, not recruiting --> Completed
- | Journal: Recent development of piperazine and piperidine derivatives as antipsychotic agents. (Pubmed Central) - Jun 22, 2021
In the present review, we include the studies related to the effect of different substituents on piperidine/piperazine derivatives and their anti-psychotic activity. Various series of synthesized compounds by different researchers with piperidine/piperazine nucleus have been reviewed and diagrammatically represented in the form of SAR (structure activity relationships) which will help to the scientists for the development of potential lead compounds.
- | MK-8435 / Merck (MSD)
Trial completion date, Trial primary completion date: Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects (clinicaltrials.gov) - Jan 8, 2021
P1, N=18, Active, not recruiting, Sponsor: Yale University
Various series of synthesized compounds by different researchers with piperidine/piperazine nucleus have been reviewed and diagrammatically represented in the form of SAR (structure activity relationships) which will help to the scientists for the development of potential lead compounds. Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Jun 2021
- | ifenprodil tartrate / Chiba University Hospital, ifenprodil (NP-120) / Algernon Pharma, MK-8435 / Merck (MSD)
Review, Journal: Glycine transporter inhibitors: a new avenue for managing neuropathic pain. (Pubmed Central) - Aug 15, 2020
In addition, the possible mechanisms of action of the GlyT inhibitors, i.e. how they affect the neurochemical and pain transmission in the spinal cord, are also discussed. The growing evidence for the possible therapeutic intervention of neuropathic pain by GlyT inhibitors further urges development of drugable compounds, which may beneficially restore impaired pain transmission in various neuropathic conditions.
- | MK-8435 / Merck (MSD)
Trial completion date, Trial primary completion date: Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects (clinicaltrials.gov) - Aug 9, 2020
P1, N=18, Active, not recruiting, Sponsor: Yale University
The growing evidence for the possible therapeutic intervention of neuropathic pain by GlyT inhibitors further urges development of drugable compounds, which may beneficially restore impaired pain transmission in various neuropathic conditions. Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Jun 2020 --> Dec 2020
- | MK-8435 / Merck (MSD)
Trial completion date, Trial primary completion date: Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects (clinicaltrials.gov) - Dec 18, 2019
P1, N=18, Active, not recruiting, Sponsor: Yale University
Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Jun 2020 --> Dec 2020 Trial completion date: Dec 2019 --> Jun 2020 | Trial primary completion date: Dec 2019 --> Jun 2020
- | MK-8435 / Merck (MSD)
Trial completion date, Trial primary completion date: Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects (clinicaltrials.gov) - Jan 9, 2019
P1, N=18, Active, not recruiting, Sponsor: Yale University
Trial completion date: Dec 2019 --> Jun 2020 | Trial primary completion date: Dec 2019 --> Jun 2020 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- MK-8435 / Merck (MSD)
Trial primary completion date: Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects (clinicaltrials.gov) - Nov 30, 2017
P1, N=18, Active, not recruiting, Sponsor: Yale University
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial primary completion date: Dec 2017 --> Dec 2018
- MK-8435 / Merck (MSD)
Trial primary completion date: Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects (clinicaltrials.gov) - Dec 5, 2016
P1, N=18, Active, not recruiting, Sponsor: Yale University
Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Dec 2016 --> Dec 2017
- MK-8435 / Merck (MSD)
Trial primary completion date: Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects (clinicaltrials.gov) - Nov 30, 2015
P1, N=18, Active, not recruiting, Sponsor: Yale University
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Dec 2015 --> Dec 2016
- MK-8435 / Merck (MSD)
Trial primary completion date: Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects (clinicaltrials.gov) - Sep 28, 2014
P1, N=18, Active, not recruiting, Sponsor: Yale University
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2013 --> Dec 2015
- MK-8435 / Merck (MSD)
Enrollment change: GUEST: Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN) (clinicaltrials.gov) - Dec 17, 2013
P2, N=0, Withdrawn, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Dec 2013 --> Dec 2015 N=200 --> 0
- | MK-8435 / Merck (MSD)
Trial termination: Trial Investigating the Efficacy and Safety of SCH 900435 (Org 25935) in Relapse Prevention in Participants With Alcohol Dependence (P05718) (clinicaltrials.gov) - Feb 5, 2013
P2, N=141, Terminated, Sponsor: Merck Sharp & Dohme Corp.
N=200 --> 0 Completed --> Terminated; Based on the outcome of a planned interim analysis, the study was stopped early due to futility.
- MK-8435 / Merck (MSD)
Enrollment change: Trial Investigating the Efficacy and Safety of SCH 900435 (Org 25935) in Relapse Prevention in Participants With Alcohol Dependence (P05718) (clinicaltrials.gov) - Feb 5, 2013
P2, N=141, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Completed --> Terminated; Based on the outcome of a planned interim analysis, the study was stopped early due to futility. N=300 --> 141
- MK-8435 / Merck (MSD)
Enrollment change: Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705) (clinicaltrials.gov) - Jan 29, 2013
P2, N=40, Terminated, Sponsor: Merck Sharp & Dohme Corp.
N=300 --> 141 N=60 --> 40